Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
Status:
Not yet recruiting
Trial end date:
2022-08-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when
combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous
non-small cell lung cancer. To explore the immunogenicity of SHR-1701 and the relationship
between corresponding biomarkers and therapeutic effect.